VNDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VNDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-01-19), the Trailing Annual Dividend Yield of Vanda Pharmaceuticals is 0.00%.
The historical rank and industry rank for Vanda Pharmaceuticals's Dividend Yield % or its related term are showing as below:
Vanda Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00.
As of today (2025-01-19), the Forward Dividend Yield % of Vanda Pharmaceuticals is 0.00%.
Vanda Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Vanda Pharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Vanda Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Vanda Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Vanda Pharmaceuticals (NAS:VNDA) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Ray Mitchell | director | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037 |
Kevin Patrick Moran | officer: VP, Acting CFO & Treasurer | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Timothy Williams | officer: SVP & General Counsel | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037 |
Joakim Wijkstrom | officer: SVP, Chief Marketing Officer | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037 |
Mihael Hristos Polymeropoulos | director, officer: Chief Executive Officer | 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850 |
Gunther Birznieks | officer: SVP, Business Development | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037 |
Tage Honore | director | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Thomas Watkins | director | 1221 GULF SHORE BLVD N #303, NAPLES FL 34102 |
Aranthan Ii Jones | officer: Chief Corp. Affairs Officer | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037 |
Phaedra Chrousos | director | 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037 |
Richard W Dugan | director | 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
James Patrick Kelly | officer: SVP, CFO, Treasurer & Secretar | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Gian Piero Reverberi | officer: SVP, General Manager Europe | 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Anne Sempowski Ward | director | C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
From GuruFocus
By PRNewswire • 06-13-2024
By PRNewswire • 10-09-2024
By PRNewswire • 09-19-2024
By Business Wire • 06-10-2024
By PRNewswire • 10-30-2024
By GuruFocus News • 11-07-2024
By PRNewswire • 11-12-2024
By GuruFocus Research • 08-01-2024
By PRNewswire • 09-11-2024
By PRNewswire • 07-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.